Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage

American Journal of Gastroenterology

Volumn 100, Issue 3, 2005, Pages 664-671

  Halpert, Albena ^a   Dalton, Christine B ^b   Diamant, Nicholas E ^b   Toner, Brenda B ^b   Hu, Yuming ^b   Morris, Carolyn B ^b   Bangdiwala, Shrikant I ^b   Whitehead, William E ^b   Drossman, Douglas A ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DESIPRAMINE; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; FECES ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PAIN ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT OUTCOME; WELLBEING;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COLONIC DISEASES, FUNCTIONAL; DESIPRAMINE; FEMALE; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 16844368627     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.30375.x     Document Type: Article

References (38)

1. Maxton DG, Whorwell PJ. Use of medical resources and attitudes to health care of patients with 'chronic abdominal pain'. Br J Med Econ 1992;2:75-9.
2. Onghena P, Houdenhove BV. Antidepressant-induced analgesia in chronic non-malignant pain: A meta-analysis of 39 placebo-controlled studies. Pain 1992;49:205-19.
3. Magni G. The use of antidepressants in the treatment of chronic pain: A review of the current evidence. Drugs 1991;42(5):730-48.
4. Pilowsky I, Barrow CG. A Controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain. Pain 1990;40:3-19.
5. Egbunike IG, Chaffee BJ. Antidepressants in the management of chronic pain syndromes. Pharmacotherapy 1990;10(4):262-70.
6. France RD, Houpt JL, Ellinwood MD. Therapeutic effects of antidepressants in chronic pain. Gen Hosp Psychiatry 1984;6:55-63.
7. Drossman DA, Camilleri M, Mayer E, et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123(6):2108-31.
8. Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with anti-depressants: A meta-analysis. Am J Med 2000;108:65-72.
9. Wald A. Psychotropic agents in irritable bowel syndrome. J Clin Gastroenterol 2002;35(Suppl):S53-7.
10. Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy vs. education and desipramine Vs. placebo for moderate to severe functional bowel disorders. Gastroenterology 2003;125(1):19-31.
11. Clouse RE. Managing functional bowel disorders from the top down: Lessons from a well-designed treatment trial. Gastroenterology 2003;125(1):249-53.
12. Clouse RE, Lustman P, Geisman RA. Antidepressant therapy in 138 patients with irritable bowel syndrome: A five-year clinical experience. Aliment Pharmacol Ther 1994;8:409-16.
13. Perry PJ, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: An estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 1994;14(4):230-40.
14. Toner BB, Segal ZV, Emmott S, et al. Cognitive behavior group therapy for patients with irritable bowel syndrome. Int J Group Psychother 1998;48(2):215-43.
15. Drossman DA, Li Z, Leserman J, et al. Health status by gastrointestinal diagnosis and abuse history. Gastroenterology 1996;110(4):999-1007.
16. Melzack R. The McGill pain questionnaire: Major properties and scoring methods. Pain 1975;1:277- 99.
17. Patrick DL, Drossman DA, Frederick IO, et al. Quality of life in persons with irritable bowel syndrome: Development of a new measure. Dig Dis Sci 1998;43(2):400-11.
18. Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-QOL: A disease specific quality of life questionnaire. Am J Gastoenterol 2000;95(4):999-1007.
19. Drossman DA, Li Z, Toner BB, et al. Functional bowel disorders: A multicenter comparison of health status, and development of illness severity index. Dig Dis Sci 1995;40(5):986-95.
20. Heaton KW, Gosh S. Relation between stool form on a seven point scale and symptoms of urgency, straining, and incomplete evacuation: A new way of looking at irritable bowel syndrome. Gut 1989;30:A1465.
21. Demyttenaere K, Enzlin P, Dewe W, et al. Compliance With antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events. J Clin Psychiatry 2001;62(Suppl 22):30-3.
22. Demyttenaere K. Compliance during treatment with antidepressants. J Affect Disord 1997;43(1):27-39.
23. Demyttenaere K, Haddad P. Compliance With antidepressant therapy and antidepressant discontinuation symptoms. Acta Psychiatr Scand Suppl 2000;403:50-6.
24. Levine RR. The role of plasma concentrations in the use of tricyclic antidepressant drugs. Prog Neuropsychopharmacol 1979;3(1-3):211-22.
25. Risch SC, Kalin NH, Janowsky DS, et al. Indications and guidelines for plasma tricyclic antidepressant concentration monitoring. J Clin Psychopharmacol 1981;1(2):59-63.
26. Risch SC, Huey LY, Janowsky DS. Plasma levels of tricyclic antidepressants and clinical efficacy: Review of the literature-part II. J Clin Psychiatry 1979;40(2):58-69.
27. Perry PJ, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: An estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 1994;14(4):230-40.
28. Perry PJ, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: An estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 1994;14(4):230-40.
29. Furukawa TA, McGuire H, Barbui C. Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: Systematic review. Br Med J 2002;325(7371):991.
30. Gorard DA, Libby GW, Farthing JG. Influence of antidepressants on whole gut orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 1994;8:159-66.
31. Gorard DA, Libby GW, Farthing MJG. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Dig Dis Sci 1995;40:86-95.
32. Gebhart GF. Visceral nociception: Consequences, modulation and the future. Eur J Anaesthesiol Suppl 1995;10:24-7.
33. Naliboff BD, Derbyshire SWG, Munakata J, et al. Cerebral activation in irritable bowel syndrome patients and control subjects during rectosigmoid stimulation. Psychosom Med 2001;63(3):365-75.
34. Mertz H; Pickens D, Morgan V. Amitriptyline reduces activation of the anterior cingulate cortex in irritable bowel syndrome patients during rectal pain. Gastroenterology 2003;124(4):A-47.
35. Drossman DA. A case of irribable bowel syndrome that illustrates the biopsychosocial model of illness. Biopsychosocial Med 2003:15-25.
36. O'Malley PG, Jackson JL, Santoro J, et al. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 1999;48(12):980-90.
37. Furukawa TA, McGuire H, Barbui C. Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: Systematic review. Br Med J 2002;325(7371):991.
38. Hollister LE. Plasma concentrations of tricyclic antidepressants in clinical practice. J Clin Psychiatry 1982;43(2):66-9.